Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 26 2015

Print RSS Feed

Financial Report: AstraZeneca

Published August 8, 2014

2Q Revenues: $6.5 billion (+4%)

2Q Earnings: $796 million (+9%)

YTD Revenues: $12.9 billion (+2%)

YTD Earnings: $1.3 billion (-4%)

Comments: Diabetes sales were up 128% following the integration of BMS assets and strong U.S. Farxiga launch. Brilinta sales were up 84% in the quarter to $117 million. Crestor sales were down 2% (CER) to $1.5 million. Symbicort sales were $928 million, up 9% (CER). Nexium sales were down 4% (CER) to $971 million. U.S. revenues were up 8%. Declining sales from brands facing generic competition such as Atacand and Seloken/Toprol-XL were offset by the inclusion of 100% of revenue from the diabetes brands. Revenue in the Rest of World (ROW) was up 1%. Revenue in Europe was flat, with the impact of Seroquel XR declines, competitive pressure for Symbicort and loss of exclusivity for Seroquel IR, Atacand and Merrem.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On